Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tarextumab | 0.81 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 26 Parkinson's papers of 2,690 | 0.57 |
| pathways Reactome | 8 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4322
Sealed predictions
- NOTCH3 in dopamine neurons, braak-0.37 (p 0.323) → -0.35 (p 0.361)receipt 4330
Swarm cases
receipt 4330: NOTCH3 in dopamine neurons, braak
- power
- full sample -0.27 (p 0.281, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.218, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.156, n 18). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.17, sign flips 0; without severely affected donors -0.27 (p 0.281, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NOTCH3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts